Table 1.
Characteristics of young adult cancer survivors (N = 24).
| Extended Survivors (n = 12) |
Long-term Survivors (n = 12) |
All Participants (N = 24) | |
|---|---|---|---|
| Age: Mean ± SD (range), years | |||
| At diagnosis | 31.2 ± 6.5 (20–39) | 25.6 ± 4.9 (19–32) | 27.8 ± 6.3 (19–39) |
| At study enrollment | 31.4 ± 6.1 (21–40) | 32.1 ± 5.3 (26–40) | 31.8 ± 5.6 (21–40) |
| Body Mass Index: Mean ± SD [range], kg/m2 | |||
| At diagnosis | 28.2 ± 6.2 (22–43) | 25.7 ± 6.7 (19–41) | 27.0 ± 8.3 (19–43) |
| At study enrollment | 29.7 ± 6.5 (21–43) | 28.8 ± 8.0 (20–44) | 29.2 ± 9.1 (20–44) |
| Female Gender: n (%) | 9 (75) | 11 (92) | 20 (83) |
| Non-Hispanic Ethnicity: n (%) | 10 (83) | 11 (92) | 21 (88) |
| White Race: n (%) | 7 (58) | 6 (50) | 13 (54) |
| Education: n (%) | |||
| Some college | 0 (0) | 5 (42) | 5 (21) |
| College degree | 8 (67) | 4 (33) | 12 (50) |
| Some graduate school | 1 (8) | 1 (8) | 2 (8) |
| Graduate school degree | 3 (25) | 2 (17) | 5 (21) |
| Cancer Diagnosis: n (%) | |||
| Acute lymphoblastic leukemia | 1 (8) | 0 (0) | 1 (4) |
| Acute myeloid leukemia | 1 (8) | 2 (17) | 3 (12) |
| Bladder | 1 (8) | 0 (0) | 1 (4) |
| Breast | 2 (17) | 2 (17) | 4 (16) |
| Colorectal | 1 (8) | 0 (0) | 1 (4) |
| Hodgkin lymphoma | 2 (17) | 2 (17) | 4 (16) |
| Melanoma | 0 (0) | 1 (8) | 1 (4) |
| Non-Hodgkin lymphoma | 1 (8) | 1 (8) | 2 (8) |
| Ovarian | 1 (8) | 0 (0) | 1 (4) |
| Sarcoma | 0 (0) | 2 (17) | 2 (8) |
| Testicular | 0 (0) | 1 (8) | 1 (4) |
| Thyroid | 2 (16) | 1 (8) | 3 (12) |
| Cancer stage: n (%) | |||
| Stage 0 | 2 (17) | 1 (8) | 3 (13) |
| Stage I | 2 (17) | 1 (8) | 3 (13) |
| Stage II | 1 (8) | 2 (17) | 3 (13) |
| Stage III | 2 (17) | 1 (8) | 3 (13) |
| Stage IV | 2 (17) | 2 (17) | 4 (16) |
| No stage; deemed aggressive | 2 (17) | 2 (17) | 4 (16) |
| Prefer not to answer | 1 (8) | 3 (25) | 4 (16) |
| Therapy received: n (%) | |||
| Chemotherapy | 4 (34) | 2 (17) | 6 (25) |
| Surgery | 2 (17) | 2 (17) | 4 (16) |
| Chemotherapy + Radiation | 1 (8) | 1 (8) | 2 (8) |
| Chemotherapy + Surgery | 1 (8) | 1 (8) | 2 (8) |
| Radiation + Surgery | 1 (8) | 0 (0) | 1 (4) |
| Chemotherapy + Immunotherapy | 1 (8) | 0 (0) | 1 (4) |
| Chemotherapy + Immunotherapy + Surgery | 0 (0) | 1 (8) | 1 (4) |
| Chemotherapy + Hormonal + Surgery | 0 (0) | 1 (8) | 1 (4) |
| Chemotherapy + Radiation + Surgery | 0 (0) | 1 (8) | 1 (4) |
| Chemotherapy + Radiation + Immunotherapy + Surgery | 1 (8) | 2 (17) | 3 (13) |
| Prefer not to answer | 1 (8) | 1 (8) | 2 (8) |
| Comorbidities: n (%) | |||
| None | 9 (75) | 8 (67) | 17 (71) |
| Obesity | 2 (17) | 3 (25) | 5 (21) |
| Hypertension | 1 (8) | 0 (0) | 1 (4) |
| Obesity + High Cholesterol | 0 (0) | 1 (8) | 1 (4) |
Note. Percentages may not sum to 100 due to rounding.